Ketamine Infusion for Chronic Pain: Evidence, Protocols, and Risks
Ketamine infusions can reduce severe neuropathic and centrally sensitised pain when standard treatment has failed. This guide covers which conditions respond, typical protocols, how long relief lasts, and the real risks of repeated use.
Analyzed Article
This fact-check analysis pertains to a specific external article.
Title: Ketamine Injection ( Read original article )
Source: U.S. National Library of Medicine
Claim-by-Claim Ledger
| ID | Claim | Risk | Verdict | Evidence | Notes |
|---|---|---|---|---|---|
| C1 | Ketamine acts primarily as an NMDA receptor antagonist, which is the basis for its effect on central sensitisation and neuropathic pain. | medium | supported | V1, V2 | It also has opioid-sparing effects. |
| C2 | Evidence supports ketamine infusion for complex regional pain syndrome and some refractory neuropathic pain, with relief typically measured in weeks to months. | high | partial | V1 | Trial quality is variable and duration of benefit inconsistent. |
| C3 | Common acute adverse effects include dissociation, hallucinations, nausea, raised blood pressure and heart rate, requiring monitored administration. | high | supported | V2, S1 | Effects are dose dependent. |
| C4 | Repeated or high-dose ketamine exposure carries risks of urinary tract damage, liver injury, cognitive effects, and dependence. | high | supported | V3 | Recognised particularly from long-term recreational use patterns. |
Why ketamine is used for pain at all
Ketamine is an anaesthetic agent that, at much lower sub-anaesthetic doses, blocks the NMDA receptor. That receptor is central to the wind-up process by which repeated pain signalling makes the spinal cord and brain progressively more responsive — the mechanism behind central sensitisation, opioid tolerance, and much refractory neuropathic pain [V1][V2]. Blocking it can, in some people, reset that amplification rather than simply mask the pain, which is why relief can outlast the drug’s presence in the body. That mechanism also explains its main clinical niches: complex regional pain syndrome, severe neuropathic pain, and situations where opioid tolerance has developed [V1][V9].
Key numbers
- 0.1–0.5 mg/kg/hour: the usual sub-anaesthetic infusion range for chronic pain; anaesthetic doses are many times higher [V1][V2].
- Weeks to ~3 months: typical duration of benefit after a course, with wide variation [V1].
- 10–15 minutes: onset of dissociative effects during infusion; they resolve within an hour or two of stopping [V2].
- 24 hours: minimum period to avoid driving or operating machinery after an infusion [S1].
Which conditions are considered
| Condition | Evidence position | Notes |
|---|---|---|
| Complex regional pain syndrome | Best supported chronic indication [V1] | Often multi-day courses |
| Refractory neuropathic pain | Supported in some trials, inconsistent [V1] | Used after standard agents fail |
| Central sensitisation syndromes, including fibromyalgia | Limited and mixed [V1][V9] | Not routine |
| Opioid tolerance and hyperalgesia | Supported as opioid-sparing adjunct [V1] | Useful during opioid reduction |
| Cancer pain | Adjunct in refractory cases [V1] | Specialist palliative settings |
| Acute perioperative pain | Well supported as adjunct [V1][V2] | Different context and dosing |
Ketamine is not a first, second, or third-line treatment for common chronic pain. It belongs after neuropathic agents, physical rehabilitation, psychological therapy, and appropriate interventional options have been genuinely tried.
What a treatment course involves
Assessment comes first: diagnosis, previous treatments, blood pressure and cardiac history, mental health history, liver function, and a clear statement of what outcome would count as success. The infusion is given in a monitored setting with intravenous access, blood pressure and heart rate monitoring, and a clinician present; some centres pre-treat with a benzodiazepine or an antiemetic to reduce dissociation and nausea [V2]. Sessions last from under an hour to several hours, and courses for complex regional pain syndrome may run over consecutive days. You need an escort home and must not drive for at least 24 hours [S1]. Because dissociative effects can be unsettling, being told in advance what they feel like substantially reduces distress.
Honest expectations
Response is bimodal: some people gain considerable relief and function, and a significant minority gain nothing. Benefit fades over weeks to months in most responders, which means ketamine is best framed as a window rather than a cure — the point of the window is to intensify rehabilitation, reduce opioid dose, and re-establish activity while pain is lower [V1][V9]. Courses that are repeated indefinitely without a functional gain to show for them are a warning sign, both clinically and for the bladder and cognitive risks that accumulate with exposure [V3].
Risks and monitoring
Acute effects — dissociation, hallucinations, raised blood pressure and heart rate, nausea, dizziness — are dose-dependent and managed by titration and monitoring [V2][S1]. The risks specific to repeated exposure are more consequential: ketamine-induced uropathy causes urinary frequency, urgency, pain, and in severe cases irreversible bladder scarring; liver enzyme abnormalities and bile duct changes occur; and memory, concentration, and mood effects, along with psychological dependence, are documented, mostly from heavy long-term use [V3]. Practical safeguards are a defined course length, a recorded functional outcome, direct questioning about urinary symptoms at every visit, periodic liver tests, and never sourcing the drug outside a monitored clinical setting.
Questions worth asking before you book
Ketamine clinics vary widely in protocol, monitoring, and cost, and few are regulated specifically for chronic pain. Reasonable questions: what diagnosis is being treated and what is the evidence for ketamine in it; what dose, duration, and number of sessions are planned; who monitors you during the infusion and what monitoring is used; what happens if you do not respond; how urinary, liver, and cognitive risks will be screened and followed [V1][V3]; and how the treatment connects to rehabilitation, medication review, or psychological support afterwards. A service that cannot describe a stop rule or an aftercare plan is offering infusions rather than pain management [V9].
The day itself, and afterwards
Plan for a longer visit than the infusion time. Eat lightly beforehand or follow the fasting instructions given, bring a companion who can take you home, and expect a period of feeling detached, dreamy, or unsteady during and shortly after the infusion — unsettling if unexpected, tolerable if anticipated [V2][S1]. Blood pressure and pulse are checked repeatedly, and the rate is reduced if dissociation is distressing. Afterwards: no driving, no alcohol, and no important decisions for at least 24 hours; mild nausea, headache, and tiredness are common that evening. Record pain and function daily for the following two weeks, because that record is what determines whether further sessions are justified [V1].
Related reading: CRPS treatment, diabetic nerve pain treatment, fibromyalgia treatment, and non-opioid pain medication options.
Frequently asked questions
Does ketamine work for chronic pain?
For selected refractory pain, yes, though not for everyone. The best-supported uses are complex regional pain syndrome and severe neuropathic or centrally sensitised pain that has not responded to standard medication [V1]. Reported relief usually lasts weeks to a few months rather than permanently, and trial quality across the literature is variable — which is why it sits as a specialist option rather than an early one [V1][V9].
How long does pain relief from a ketamine infusion last?
Commonly a few weeks to around three months after a course, with wide individual variation; some people get no benefit and others get months [V1]. Response is judged on function and pain scores at defined follow-up points, and maintenance infusions or oral follow-on treatment are considered only in people who clearly responded. Repeating an ineffective course at higher dose is not appropriate.
What is a typical ketamine infusion protocol for pain?
Sub-anaesthetic dosing given intravenously under monitoring, usually in the range of roughly 0.1 to 0.5 mg/kg/hour, over sessions lasting from under an hour to several hours, sometimes repeated daily over several days for conditions such as complex regional pain syndrome [V1][V2]. Protocols vary widely between centres because no single regimen is established. Blood pressure, heart rate, and sedation are monitored throughout.
What are the side effects of ketamine infusions?
During the infusion: dissociation or feeling detached, vivid dreams or hallucinations, dizziness, blurred vision, nausea, and increases in blood pressure and heart rate [V2][S1]. Afterwards: drowsiness for hours, so you cannot drive. With repeated or high cumulative exposure: bladder inflammation and scarring, liver abnormalities, memory and concentration problems, and dependence [V3]. Monitoring and dose limits exist for these reasons.
Who should not have ketamine infusion therapy?
It is generally avoided in poorly controlled hypertension, significant cardiac disease, raised intracranial or intraocular pressure, active psychosis, current substance misuse involving ketamine, significant liver disease, and pregnancy [V2][V3][S1]. A history of psychosis or of ketamine misuse needs specialist assessment before treatment is considered. Bladder symptoms during a course are a reason to stop and reassess.
References
- [V1] Bell RF, Kalso EA. Ketamine in Acute and Chronic Pain Management. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-04.
- [V2] Rosenbaum SB, et al. Ketamine. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-04.
- [V3] Orhurhu VJ, et al. Ketamine Toxicity. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-04.
- [V9] Dydyk AM, Conermann T. Chronic Pain. StatPearls, NCBI Bookshelf. 2026. Source . Accessed 2026-08-04.
- [S1] U.S. National Library of Medicine. Ketamine Injection. MedlinePlus. 2026. Source . Accessed 2026-08-04.
Editorial Notes
Educational review only. This content is not personalized medical advice, diagnosis, or treatment.
Explore More In This Topic
Looking for additional coverage in this category? Browse all Ketamine Infusion Therapy fact checks.